A study published in the Journal of Managed Care & Specialty Pharmacy found that filgrastim and filgrastim-sndz were noninferior for the prevention of febrile neutropenia events that would require ...

In 2015 the Food and Drug Administration approved filgrastim-sndz (Zarxio), the first US biosimilar. Following rapid uptake, by March 2018 filgrastim-sndz accounted for 47 percent of filgrastim ...

The first biosimilar product in the United States has been approved by the US Food and Drug Administration, in a move described by the agency's director, Janet Woodcock, as a "significant milestone." ...

Healthcare resource utilization and total cost of care in older patients with acute myeloid leukemia ineligible for intensive chemotherapy.

Please provide your email address to receive an email when new articles are posted on . There was a substantial uptake in the use of alternative filgrastim products, including its biosimilar ...

Biologics used to treat patients can be incredibly expensive, so there was significant hope that biosimilar drugs—which are highly similar to an existing biologic drug on the market—could serve as a ...

Experience of financial burden and distress among people with ovarian cancer. PP (comparator) vs. SP (reference) using filgrastim-sndz.

Please provide your email address to receive an email when new articles are posted on . The use of biosimilar biologics filgrastim-sndz and tbo-filgrastim increased substantially among Medicare ...